As a venture partner at IDEO CoLab Ventures, Williams invests in early-stage companies at the intersection of design, technology, and network effects. The portfolio spans fintech, decentralized systems, Web3, future of work, and AI. IDEO CoLab Ventures has made 86 investments since 2015, with the latest in RockSolid, a financial software company, in September 2025.
But Williams also mentors at IndieBio, the biotech accelerator. This is where the synthetic biology PhD actually matters. When a founder pitches a company based on CRISPR gene editing or engineered probiotics or cell-free protein synthesis, Williams knows which parts are hard because biology is hard and which parts are hard because the founder hasn't done the reading.
He writes, too. Medium articles on living data streams, internet-connected solar panels, blockchain applications for IoT. Technical but readable. The kind of writing that happens when someone actually builds things and then tries to explain them, instead of the kind that happens when someone reads other people's explanations and repackages them with more buzzwords.
The through-line in Williams' career isn't obvious until you squint at it. Sun Microsystems taught him ecosystems. MIT taught him systems. UCSF taught him that biological systems are just regular systems that are allowed to be wet and unpredictable. IDEO taught him that design isn't decoration, it's how you make complex things legible. Kindred taught him that robots are harder than anyone thinks. Computable taught him that data streams are rivers, not lakes.
What he's doing now is taking all of that and pointing it at early-stage companies. Not the late-stage "we need $50M to scale" companies. The early ones. The "we have an idea and three months of runway" ones. The ones where the founder is still writing code at 2am and hasn't hired a Head of Growth because they don't have growth to head.
Williams operates at the intersection of three fields that don't usually talk to each other: synthetic biology, artificial intelligence, and decentralized systems. Synthetic biology is about programming cells. AI is about programming computers to learn. Web3 is about programming incentives without a central authority. All three are about taking dumb components and arranging them so intelligence emerges.
The interesting thing about Williams isn't that he knows a lot - plenty of people know a lot. It's that he's built things in wildly different domains and seen what actually transfers. The design process for a synthetic biology circuit transfers to designing a machine learning pipeline. The debugging process for robotics transfers to debugging a DAO's governance system. The questions you ask when a cell isn't responding transfer to the questions you ask when users aren't converting.
He joined Twitter in December 2007. Early adopter. Uses the handle _reidw_ everywhere - Twitter, Medium, Mastodon. Consistent personal branding before personal branding was a thing people hired consultants for. Based in San Francisco, because of course he is. That's where the density is. The collision rate between smart people with different expertise.
Williams' research advisor at UCSF, Wendell Lim, is a pioneer in engineering therapeutic T cells for cancer treatment. Lim's lab doesn't just study how cells work - they rebuild them to do new things. CAR-T cells that hunt tumors. Synthetic gene circuits that implement logic gates. It's less biology and more electrical engineering, except the circuits are made of proteins and the components sometimes evolve when you're not looking.
That's the world Williams came from. Where you don't just accept what biology gives you. Where you design, test, iterate. Where failure is cheap if you catch it early and expensive if you don't. Where the method matters more than the credentials.
Now he's bringing that method to venture capital. Most VCs pattern-match - this startup looks like that successful startup, so invest. Williams actually understands what's under the hood. He can read a technical whitepaper and spot the hand-waving. He can look at a go-to-market strategy and see where it depends on user behavior that won't happen. He can tell the difference between a hard technical problem and an impossible one.
WE3, his design collective, invests what they call "creative capital" - not just money, but design work, product thinking, brand development. It's the kind of help that matters more at the beginning than the end. Anyone can help you scale. Fewer people can help you figure out what to build in the first place.
The broader pattern here is people who refuse to stay in one box. Williams could have stayed in academic biology. Become a professor. Written grants. Trained grad students. Respectable career. Instead, he kept moving toward the places where different fields collide - where the people who know biology don't know design, and the people who know design don't know code, and the people who know code don't know how to sell.
Those collision points are where the interesting work happens. Where someone needs to translate between worlds. Where the standard playbook doesn't exist yet because the game is too new. Where being fluent in multiple languages - cell signaling, machine learning, product design, venture capital - means you can see connections other people miss.
Williams is building things and funding people who build things. The things are different - synthetic biology, Web3, robotics, AI - but the process is the same. Figure out what's actually hard. Build the simplest version that could work. Test it against reality, not your assumptions. Iterate fast. Kill the bad ideas before they kill you.
It's not a romantic vision of venture capital. No talk about changing the world or making a dent in the universe. Just the workmanlike process of helping people who are trying to build something difficult actually pull it off. Which, in the end, might be more useful than inspiration.
